Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Research facility

Location: Napoli, Italy (IT) IT

ISNI: 0000000417608805


Show on Map:


Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year




Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study (2024) Wies C, Schneider L, Haggenmüller S, Bucher TC, Hobelsberger S, Heppt M, Ferrara G, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study (2023) Medas F, Dobrinja C, Al-Suhaimi EA, Altmeier J, Anajar S, Arikan AE, Azaryan I, et al. Journal article Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors (2023) Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer (2023) Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JKJ, Zlobec I, et al. Journal article Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, et al. Journal article S02-5 Physical inactivity in nine Eastern European and Central Asian countries: results from the WHO STEPwise approach to NCD risk factor surveillance (2022) Whiting S, Mendes R, Abu-Omar K, Gelius P, Crispo A, Mccoll K, Simmonds P, et al. Conference contribution Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution
1 2 3 4